Sweden Advises Against Costly New ALS Drug Due to Limited Benefits
The regions are advised against using a new medication for the nervous disease ALS. The treatment is deemed too expensive and not to have any tangible impact on the patients.
Sweden
Upwards on Wall Street – major companies recovered
The trading week on Wall Street ended in major, after many large technology companies had a shaky week.
Business
Alzheimer's drug rejected by EMA
The Alzheimer's drug lecanemab has not been approved by the European Medicines Agency EMA. The benefits are not considered to outweigh the potential drawbacks. A review of the decision will be requested, announces Swedish Bioarctic – whose share plummeted on the news.
Sweden